Live Breaking News & Updates on Exeter Science|Page 4

Stay updated with breaking news from Exeter science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Oxford/AstraZeneca vaccine 80 per cent effective against B1.617.2 variant: UK study

1354
People wearing protective face masks wait to receive their second dose of COVISHIELD, a coronavirus disease (COVID-19) vaccine manufactured by Serum Institute of India, outside a vaccination centre in Kolkata on May 12, 2021. Reuters file photo
London, May 22
Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of COVID-19, first discovered in India, a new UK government study has reportedly found.
The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as Covishield and being administered among the adult population in India to protect against the deadly virus. ....

United Kingdom , City Of , North Yorkshire , Matt Hancock , Oxford Astrazeneca , Jeffrey Barrett , Sanger Institute , Environment Agency , Virus Threats Advisory Group Nervtag , National Health Service , United Kingdom Health , Biosecurity Centre Dr Andrew Engeli , Department Of Health , Public Health England , Serum Institute Of India As Covishield , Serum Institute , Emerging Respiratory Virus Threats Advisory Group , United Kingdom Health Secretary Matt , Social Care , Chief Executive , Exeter Science , Programme Lead , Joint Biosecurity Centre Dr Andrew , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , வடக்கு யார்க்ஷயர் ,

COVID-19: UK study shows AstraZeneca vaccine 80% effective against B1.617.2 variant

The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as Covishield and being administered among the adult population in India to protect against the deadly virus ....

United Kingdom , North Yorkshire , Matt Hancock , Oxford Astrazeneca , Jeffrey Barrett , Sanger Institute , Environment Agency , Virus Threats Advisory Group Nervtag , National Health Service , United Kingdom Health , Biosecurity Centre Dr Andrew Engeli , Department Of Health , Public Health England , Serum Institute Of India As Covishield , Serum Institute , Emerging Respiratory Virus Threats Advisory Group , United Kingdom Health Secretary Matt , Social Care , Chief Executive , Exeter Science , Programme Lead , Joint Biosecurity Centre Dr Andrew , Astrazeneca Vaccine , Astrazeneca Vaccine News , Oxford Astrazeneca Vaccine , Xford Astrazeneca Vaccine Uk Study ,

2 doses of AstraZeneca/Pfizer Covid vaccines provide 80% protection against variant found in India: UK study

A new UK government study shows that two doses of either the AstraZeneca or Pfizer Covid vaccine provide more than 80 per cent protection against the variant first found in India. ....

United Kingdom , North Yorkshire , Matt Hancock , Oxford Astrazeneca , Jeffrey Barrett , Sanger Institute , Environment Agency , Virus Threats Advisory Group Nervtag , National Health Service , United Kingdom Health , Biosecurity Centre Dr Andrew Engeli , Department Of Health , Public Health England , Serum Institute Of India As Covishield , Serum Institute , Emerging Respiratory Virus Threats Advisory Group , United Kingdom Health Secretary Matt , Social Care , Chief Executive , Exeter Science , Programme Lead , Joint Biosecurity Centre Dr Andrew , Covid Variant , Astrazeneca Vaccine , Pfizer Vaccine , Covid Vaccine ,

Oxford/AstraZeneca vaccine 80% effective against B1.617.2 variant, says U.K. study

Oxford/AstraZeneca vaccine 80% effective against B1.617.2 variant, says U.K. study
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.

Matt Hancock , Oxford Astrazeneca , Jeffrey Barrett , Sanger Institute , Environment Agency , Virus Threats Advisory Group Nervtag , National Health Service , Biosecurity Centre Dr Andrew Engeli , Uk Health , Department Of Health , Public Health England , Serum Institute Of India As Covishield , Serum Institute , Emerging Respiratory Virus Threats Advisory Group , Ssecretary Matt , Social Care , Chief Executive , Security Agency Dr Jenny , Exeter Science , Programme Lead , Joint Biosecurity Centre Dr Andrew , மேட் ஹான்காக் , ஜெஃப்ரி பாரெட் , சாங்கர் நிறுவனம் , தேசிய ஆரோக்கியம் சேவை , இங்கிலாந்து ஆரோக்கியம் ,

COVID-19: UK study shows AstraZeneca vaccine 80% effective against B1.617.2 variant

COVID-19: UK study shows AstraZeneca vaccine 80% effective against B1.617.2 variant
businesstoday.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesstoday.in Daily Mail and Mail on Sunday newspapers.

United Kingdom , North Yorkshire , Matt Hancock , Oxford Astrazeneca , Jeffrey Barrett , Sanger Institute , Environment Agency , Virus Threats Advisory Group Nervtag , National Health Service , United Kingdom Health , Biosecurity Centre Dr Andrew Engeli , Department Of Health , Public Health England , Serum Institute Of India As Covishield , Serum Institute , Emerging Respiratory Virus Threats Advisory Group , United Kingdom Health Secretary Matt , Social Care , Chief Executive , Exeter Science , Programme Lead , Joint Biosecurity Centre Dr Andrew , ஒன்றுபட்டது கிஂக்டம் , வடக்கு யார்க்ஷயர் , மேட் ஹான்காக் , ஜெஃப்ரி பாரெட் ,